

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesistinnen und Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Amyotrophic lateral sclerosis

orphan**anesthesia**

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 17 | 2026

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patientinnen und Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patientinnen und Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesistinnen und Anästhesisten damit keine Erfahrungen gesammelt haben, sodass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem eine Anästhesistin bzw. ein Anästhesist sowie eine weitere Krankheitsexpertin bzw. ein weiterer Krankheitsexperte (z. B. Pädiaterin bzw. Pädiater oder Neurologin bzw. Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, sodass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

**Bisher in A&I publizierte
Handlungsempfehlungen finden
Sie unter:**

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

**Dr. med. Christine Gaik,
DESAIC, FESAIC**

Oberärztin
Klinik für Anästhesie und
Intensivtherapie
Universitätsklinikum Gießen
und Marburg GmbH,
Standort Marburg
Baldingerstraße
35033 Marburg, Deutschland
E-Mail:
gaikc@med.uni-marburg.de

**Priv.-Doz. Dr. med.
Philipp Gude, MHBA**

Geschäftsführender Oberarzt
Klinik für Anästhesiologie und
Intensivmedizin
Universitätsklinikum
St. Elisabeth-Hospital
Bleichstraße 15
44787 Bochum, Deutschland
E-Mail:
philipp.gude@ruhr-uni-bochum.de

orphan**a**nesthesia

Anesthesia recommendations for Amyotrophic lateral sclerosis

Disease name: Amyotrophic lateral sclerosis

ICD 10: G12.2

Synonyms: Charcot disease, Lou Gehrig's disease

Disease summary: Amyotrophic lateral sclerosis (ALS) is a rare progressive, paralytic disorder characterized by degeneration of upper and lower motor neurons in the motor cortex, brainstem, and spinal cord. It represents the most common form of degenerative motor neuron disease [1-4]. Involvement of the upper motor neurons causes weakness, spasticity, hyperreflexia, and Babinski signs, whereas degeneration of the lower motor neurons results in weakness, muscular atrophy, fasciculations, and cramps [4]. Brainstem involvement may lead to bulbar symptoms.

The clinical course varies depending on the initially affected region and presenting symptoms, but respiratory failure is typically the final cause of death [5]. The worldwide incidence is approximately 1/50,000 per year, and the prevalence around 1/20,000. These rates are relatively uniform across Western countries, although higher frequency has been observed in the Western Pacific [6]. Both incidence and prevalence increase with age [1].

The mean age of onset for sporadic ALS is late 50s, while familial cases may present earlier. There is a slight male preponderance in sporadic cases (male to female ratio ~ 1.5-2:1), whereas familial cases show an equal distribution [1, 6]. Approximately 5-10 % of ALS cases are familial (typically autosomal-dominant inheritance), while 90-95 % occur sporadically. However, both forms are clinically indistinguishable [1, 3].

More than 40 genes have been associated with ALS, although the pathogenetic mechanism(s) remain unknown [7]. Interestingly, different mutations can result in distinct phenotypes (e.g., similar age of onset, site of onset, and disease duration), whereas identical gene mutations may lead to multiple phenotypic presentations [3]. Current research focuses on genes involved in cytoskeletal dynamics, protein and RNA homeostasis, and trafficking processes [1].

Environmental factors are believed to influence disease pathogenesis, though their precise roles are not yet clear. Reported risk factors include military service, different kinds of (head) trauma, smoking and exposure to heavy metals and pesticides [1].

ALS displays marked phenotypic heterogeneity with respect to onset, distribution, and neuronal populations affected, resulting in diverse clinical manifestations [1, 3, 8]. "Classical" ALS typically begins with focal limb weakness, progressing within weeks to months to involve most skeletal muscles. Notably, ocular and bladder muscles usually remain spared until late in the disease course [1, 3]. In addition to weakness, muscle atrophy, fasciculations, spasticity and hyperreflexia are common [8].

► **Citation:** Gaik C, Wiesmann T: Amyotrophic lateral sclerosis. *Anästh Intensivmed* 2026;67:S195–S209. DOI: 10.19224/ai2026.S195

About one-third of patients initially present with bulbar symptoms such as dysphagia, dysarthria, drooling and slurred speech [1, 9]. Dysphagia may eventually lead to aspiration of liquids and solids [10]. Emotional lability caused by involvement of frontopontine motor neurons can manifest as pseudobulbar palsy, characterized by facial spasticity and inappropriate laughter or crying in response to minor emotional stimuli [1]. Up to 50 % of patients develop behavioral or cognitive changes, 5-15 % meeting the criteria for (frontotemporal) dementia [11].

Beyond “classical” ALS, several related motor neuron disorders within the ALS spectrum (“non-classical” or “atypical forms”) exist, including those with predominant upper or lower motor neuron involvement and slower progression, such as Primary Lateral Sclerosis (PLS) and Progressive Muscular Atrophy (PMA) [7]. ALS shows marked heterogeneity in the degree of upper and lower motor neuron involvement, affected regions, cognitive or behavioral changes, and rate of progression [3, 7].

The average time from symptom onset to diagnosis is approximately 12 months. Diagnosis is primarily clinical, supported by the Gold coast criteria (or the revised El Escorial and Awaji criteria), imaging (head, spine), electromyography, and laboratory testing to exclude alternative causes of paralysis [1, 7]. Disease progression and functional impairment can be monitored using the ALS Functional Rating Scale-Revised (ALSFRS-R) [4].

Currently, no curative therapy exists for ALS. Treatment options are usually palliative and focus on symptom control through interventions such as nasogastric feeding, speech-assistive surgery, cough-assist devices, diaphragmatic pacing, ventilatory support or tracheostomy. Botulinum toxin B, as a supportive symptomatic therapy, can reduce sialorrhea in ALS patients [12]. The survival benefit of gastrostomy remains controversial [13-15]. Discussions about tracheostomy and long-term ventilation are integral to ethical considerations in advanced care planning, as these interventions may prolong life but can lead to a locked-in state with complete paralysis and loss of communication.

Pharmacologic options such as riluzole offer only modest benefit [1]. Edaravone has been approved for ALS in numerous countries, its clinical benefit remains debated, and it has not achieved approval in all regions worldwide [16]. In addition, several new and experimental disease-modifying therapies are currently under development [11].

Given the lack of effective disease-modifying treatments, the overall prognosis is poor [1, 17]. Progressive weakness of the diaphragm and respiratory muscles leads to dyspnea, orthopnea, hypoventilation, pneumonia and finally death from respiratory failure or complications such as dysphagia or immobility within 3-5 years [1, 4, 8]. The mean life expectancy after symptom onset is approximately three years [4]; however, about 20% of patients survive for five to ten years, and around 10% live longer than ten years with a slower disease progression [18].

Diagnosis may be incorrect; if uncertainty exists, the diagnosis should be re-evaluated.

Every patient is unique; individual circumstances must always guide clinical care.

Medicine is in progress; new clinical knowledge may not be yet reflected in this guideline. Perhaps new knowledge.



Recommendations are not rules or laws; they provide a framework to support clinical decision-making. Although this recommendation has passed a structured review process, it does not meet the formal criteria of a guideline.

Translations may not always reflect the most recent updates of the English version.



Find more information on the disease, its centers of reference and patient organizations on Orphanet: www.orpha.net

Emergency information

A	AIRWAY / ANESTHETIC TECHNIQUE	Prepare for difficult airway due to spasticity and cramps (mouth opening / neck and jaw mobility?), tracheal constriction / scar after tracheotomy – frequent pulmonary dysfunction with (severe) restrictive pattern – suction availability (bulbar symptoms) – consider glycopyrrolate for premedication – consider synchronization of respirator and diaphragmatic pacing system (if applicable) – no general (dis)advantage for GA (TIVA / balanced) or RA – peripheral / neuraxial RA should be considered as safe and feasible alternative – consider NIV during RA – anticipate increased autonomic dysfunction during neuraxial RA
B	BLOOD PRODUCTS (COAGULATION)	No specific recommendations
C	CIRCULATION	Treat hypovolemia (malnutrition, dehydration, autonomic dysfunction) – apparent primarily after induction – consider IBP measurement
D	DRUGS	No risk for MH – use short acting agents for GA – restrictive use of opioids, NDMR and sedative agents – avoid succinylcholine (hyperkalemia)
E	EQUIPMENT	Anesthetic-depth (e.g., BIS) and neuromuscular monitoring recommended – use ultrasound for vessel cannulation / RA – patient positioning with caution (spasticity, muscle weakness) – prefer upper position in PACU / IMC / ICU, anticipate respiratory complications with necessity of airway suctioning and allow disposability for patient's own e.g., ventilator- / cough-assist devices and caregiver

Typical surgery and procedures

Tracheostomy.

Suprapubic bladder catheterization.

Laparoscopic placement of diaphragmatic pacing systems [14, 19].

Gastrostomy: percutaneous endoscopic gastrostomy (PEG)*, percutaneous radiologic gastrostomy (PRG), per-oral image-guided gastrostomy (PIG), surgical gastrostomy (laparotomy and laparoscopy approaches have higher complications and mortality rates and are therefore less common) [10, 13, 20].

Type of anesthesia

Surgical interventions requiring general (GA) or regional (RA) anesthesia may accelerate the progression of ALS, even during minor procedures such as PEG [21, 22]. Direct influence of anesthetic agents, inflammation, and hypoperfusion, among other factors, are discussed as contributing mechanisms. Furthermore, repeated exposure to surgery and anesthesia may considerably increase the risk of respiratory complications in these patients [23].

Each anesthetic technique presents specific challenges in ALS, which must be carefully evaluated [24, 25]. GA with invasive ventilation can lead to complications such as prolonged postoperative ventilation, perioperative worsening of respiratory muscle weakness with ensuing respiratory failure, hypoventilation, an increased aspiration risk due to bulbar symptoms, and weaning difficulties. The use of short acting anesthetic – ideally avoiding muscle relaxants when feasible – may help mitigate some of these risks [9, 14, 26, 27]. Many procedures for which muscle relaxation is typically used have been successfully performed without relaxants in ALS patients, including lung surgery [28]. Furthermore, a restrictive use of opioids, sedatives and neuromuscular blocking agents is advised due to the presumed increased sensitivity of ALS patients these drugs.

Depending on the surgical procedure, RA (peripheral/neuraxial) should be strongly considered as safe and feasible alternative to avoid airway manipulation, invasive ventilation, and the use of sedatives or muscle relaxants [8, 29]. In patients with severe preexisting respiratory weakness, non-invasive ventilation (NIV) during RA may support respiratory function [9, 30]. RA can also provide effective analgesia, thereby reducing the need for systemic analgesics and their associated side effects [10].

The initiation of neuraxial (especially spinal) RA may cause hypotension and bradycardia due to local sympathectomy, as in other patients undergoing neuraxial blockade. In ALS, this may theoretically be exacerbated by varying degrees of autonomic dysfunction. Optimizing fluid balance before spinal anesthesia can help minimize hemodynamic instability. Furthermore, appropriate monitoring – non(invasive) or invasive (e.g., arterial line) – and the availability of vasoactive drugs are recommended for prompt management of hemodynamic changes [8].

Patients with preexisting CNS disorders, including those with ALS, are thought to be at increased risk of postoperative neurologic deterioration (“double-crush” phenomenon), where preexisting neural impairment and demyelination (“first crush”) may predispose to secondary injury through mechanisms such as needle trauma, technical challenges, local anesthetic neurotoxicity, or the use of specific substances (e.g., vasopressors or lidocaine) (“second crush”) [8, 31, 32]. However, there is still discordance among experts regarding the causation or even the existence of this phenomenon [33].

Nevertheless, when the surgical procedure does not require deep muscle relaxation or is confined to the extremities, RA may be preferred over GA to reduce respiratory complications [2, 8]. Various RA techniques have been successfully used in ALS patients without worsening neurological symptoms. Reported examples include epidural, spinal, or combined spinal-epidural (CSE) anesthesia for abdominal and lower limb surgery; paravertebral block for radiologic gastrostomy placement; scalp block for neurosurgery; rectus sheath block for PEG; and sacral / lumbar plexus, sciatic, adductor canal and transversus abdominis plane (TAP) block for abdominal, anorectal and lower limb surgery – even in outpatient settings [2, 10, 24, 29, 34-44]. Bilateral dual TAP block – with injections into the upper intercostal and lateral TAP compartments – may even allow abdominal surgery in ALS patients to be performed without muscle relaxants [39].

Currently, there is no universally accepted or evidence-based recommendation regarding the optimal anesthetic approach – GA vs. RA – for ALS patients. The choice should be individualized on a case-by-case basis, incorporating a thorough risk-benefit assessment, patient preferences, and coordinated multidisciplinary perioperative approach [8].

Necessary additional preoperative testing (beside standard care)

There is no standardized recommendation or protocol for the preoperative assessment of ALS patients. Evaluation should be individualized, taking into account the specific condition of each patient, in close collaboration between the anesthesiologist, neurologist, and other involved clinicians. Depending on comorbidities, preoperative assessment should focus on detecting organ dysfunction, with particular attention to the pulmonary status.

ALS patients frequently undergo pulmonary function testing (e.g., spirometry), and parameters such as SNIP, FVC, FEV₁, FEV₁ / FVC should be reviewed preoperatively as key indicators to determining the need for postoperative monitoring, respiratory support like NIV or possibly prolonged invasive ventilation [4, 45].

If postoperative NIV is anticipated, it is advisable to initiate this therapy before surgery to allow the patient to develop mask tolerance prior to its postoperative use [14]. Additional diagnostic studies (e.g., chest X-ray, ECG, echocardiography, laboratory tests, blood gas analysis) should be performed on an individual basis and clinical findings.

Particular preparation for airway management

Evaluation and preparation for airway management in ALS patients should generally follow standard guidelines for airway management. A thorough airway assessment is essential, with special attention to anatomic and dysmorphic features such as spasticity or tracheal narrowing and scarring after previous tracheostomy. Clinicians should be aware that macroglossia due to denervation-related pseudohypertrophy can rarely occur in ALS, potentially complicating airway management [46, 47].

In tracheotomized patients, the medical history should include details about any complications related to the artificial airway – such as scars, problems during tracheostomy tube changes, and the frequency of suctioning. Anticipation of a difficult airway is crucial, and appropriate backup strategies should be planned in advance.

Because pulmonary dysfunction is common in ALS, adequate preoxygenation is essential. Bag-mask-ventilation may be challenging due to spasticity and the often (severe) restrictive

ventilatory pattern. Therefore, adjunct devices (e.g., oropharyngeal (Guedel) or nasopharyngeal airway) and sufficient trained personnel should be readily available. Laryngoscopy and intubation may also be challenging. Thus, videolaryngoscopy or fiberoptic techniques can be valuable and sometimes necessary [4].

Oral and tracheal suction should be available during intubation because of frequent dysphagia and secretion management issues. Premedication with an antisialagogue such as glycopyrrolate may reduce secretion [5, 19, 48]. Although endotracheal intubation remains the preferred method for airway protection in most non-tracheotomized ALS patients, the use of a laryngeal mask may be a viable option in selected patients [31].

Particular preparation for transfusion or administration of blood products

No specific recommendations. No typical bleeding disorders were reported in ALS patients.

Particular preparation for anticoagulation

There are no specific recommendations for anticoagulation in ALS patients. However, given the frequently limited mobility and the possibility of patients being bedridden, anticoagulation should be considered on an individual basis in accordance with current guidelines, taking into account the surgical procedure and the patient's comorbidities. Furthermore, the use of compression stockings and physiotherapy may be beneficial for the prevention of deep vein thrombosis.

Particular precautions for positioning, transportation and mobilization

Many ALS patients require varying degrees of assistance with daily activities, including positioning and movement, due to physical disability and muscle weakness. Spasticity, muscle cramps, atrophy and weakness necessitate extremely careful positioning and mobilization. Surgery in the prone position (and under spinal anesthesia) has been reported without complications; however, this approach should be carefully considered in awake ALS patients without secured airway [49]. The supine position – such as in the postoperative setting – may also be stressful for ALS patients, as the use of accessory muscles is often required to maintain adequate respiration [9]. An upper or semi-sitting position may therefore help to facilitate breathing and improve respiratory comfort [30, 42].

Interactions of chronic disease and anesthesia medications

The therapeutic ALS drug riluzole has been shown to decrease the MAC of isoflurane in animal studies [50]. However, no data/reports on such interactions are available in humans. In patients receiving chronic riluzole therapy, we recommend the use of anesthetic-depth monitoring (e.g., BIS monitoring) to ensure an adequate level of anesthesia.

Anesthetic procedure

Preoperative evaluation: See details above.

Premedication: Should be administered after weighing the individual risks and benefits. Anesthesiologists must consider the increased sensitivity of ALS patients to sedative agents and their elevated risk of hypoxemia, airway obstruction, and aspiration. Benzodiazepines and gabapentinoids should only be used after careful risk-benefit evaluation [51]. Glycopyrrolate may be used as an antisialagogue to reduce salivary secretion.

Vascular access: May be difficult due to spasticity or muscle cramps. Ultrasound guidance or the use of a vein finder can facilitate successful cannulation.

(Monitored) Sedation: Agents such as fentanyl, midazolam, ketamine, dexmedetomidine, remimazolam and propofol may be used either as a sole technique or in combination with RA. Providers should consider a potential increased sensitivity of ALS patients to opioids and sedatives. Ideally, sedation should allow purposeful response to tactile and verbal stimuli, while avoiding the loss of airway and protective reflexes [8].

Induction of anesthesia: Should take into account patient-specific risk factors, particularly respiratory impairment. Due to dysphagia, malnutrition, and dehydration, hypovolemia should be anticipated. (Severe) Hypotension following induction may occur and should be assessed and anticipated using clinical evaluation, passive leg raising, transthoracic echocardiography, hemodynamic monitoring, or lactate measurement. Autonomic nervous system involvement – particularly sympathetic dysfunction – is under discussion in ALS and may lead to abnormal or inadequate hemodynamic responses, posing a risk of sudden instability [52].

Anesthetic drugs: The use of standard agents for induction and maintenance of anesthesia has generally been reported as uneventful. However, drug selection and dosing should be approached cautiously, as adverse effects may be pronounced and emergency situations more likely than in healthy individuals [52]. Non-depolarizing muscle relaxants (NDMR) should be used sparingly and at the lowest effective dose, ideally guided by quantitative neuromuscular monitoring. Succinylcholine should be avoided whenever possible due to the risk of hyperkalemia [8, 45].

Following reversal of NDMR, anesthesiologists should remain alert for residual or recurrent muscle weakness necessitating continued ventilatory support. Both sugammadex and neostigmine combined with glycopyrrolate have been successfully used to reverse NDMRs in ALS patients [2, 4, 48, 53, 54]. However, neuromuscular recovery may be delayed after the use of sugammadex in ALS [5]. When using cholinesterase inhibitors, the longer duration of action of most NDMRs compared with agents such as neostigmine should be taken into account [53]. The choice of reversal drug and its dosage should be appropriate to the degree of neuromuscular blockade, and adequate reversal must be confirmed through monitoring to prevent residual paralysis [5]. Depending on risk assessment, GA without muscle relaxants may be a viable option [6, 26, 55].

Total intravenous (TIVA) and balanced anesthesia using volatile anesthetics are both considered safe. However, volatile anesthetics have been controversially discussed regarding residual muscle relaxation – despite reversal and normal neuromuscular monitoring – as well as the possible influence on disease progression. Although current evidence does not clearly demonstrate an advantage of TIVA over inhalational anesthesia in ALS, anesthesiologists should remain aware of these considerations. When volatile anesthesia is used, desflurane and sevoflurane are preferred for maintenance due to their low lipid solubility, which allows for rapid titration and emergence [2, 45].

Regional, neuraxial, and infiltration anesthesia: When using standard agents, RA techniques have not been associated with specific complications in ALS patients [4, 29, 49]. Ultrasound guidance aids in identifying target structures, particularly in patients with spasticity, deformities, or muscle atrophy. In cervical or brachial plexus blocks, it also helps to reduce the risk of phrenic or recurrent laryngeal nerve anesthesia, which could worsen respiratory compromise.

Ventilation: Should be as lung protective as possible. In patients with a diaphragmatic pacing system, synchronization of the device with the anesthesia workstation ventilator may facilitate ventilation and postoperative weaning [14]. Preoperative consultation with the patient's referral or neuromuscular center is recommended to optimize perioperative management of such devices.

Particular or additional monitoring

Depending on the severity of pulmonary impairment, an arterial line may be placed perioperatively for blood gas monitoring [30]. Furthermore, ALS patients may have an increased risk of sudden hemodynamic instability during anesthesia due to involvement of the autonomic nervous system [52].

Despite the presence of cognitive dysfunction or a locked-in state in some patients, bispectral index (BIS) monitoring has been reported to provide a reliable estimation of anesthetic depth comparable to that in healthy individuals [56]. Neuromuscular monitoring is indispensable when muscle relaxants are used as a part of GA [2]. However, clinicians should be aware of possible discrepancies between measured neuromuscular response and clinical signs [2, 53, 55]. A Train-of-Four (TOF) ratio > 0.9 should therefore not be considered an absolute criterion for safe extubation or complete recovery from neuromuscular blockade in ALS patients [2, 54].

Possible complications

Patients with ALS are at high anesthetic risk, with pronounced respiratory depression and increased sensitivity to hypnotic agents [38]. They are especially susceptible to respiratory exhaustion and failure after neuromuscular blockade, mechanical ventilation, or aspiration pneumonia, which may necessitate prolonged mechanical ventilation or re-intubation [4, 8, 22, 38]. Weaning from ventilatory support is frequently prolonged and challenging [23, 57]. Bulbar symptoms, especially dysphagia, increase the perioperative risk of aspiration. Additionally, dysregulation or exacerbation of bulbar and autonomic nervous system involvement may contribute to perioperative complications [8].

Postoperative care

Postoperative care should be individualized according to disease severity, surgical procedure, and anesthetic technique. Patients with ALS often show increased sensitivity to muscle relaxants and opioids, predisposing them to postoperative respiratory failure and aspiration pneumonia. Poor nutritional status may cause electrolyte abnormalities and hypovolemia, while surgical stress can further exacerbate neurological symptoms [8].

Admission to an IMC or ICU may be advisable, particularly for patients with severe pre-existing respiratory dysfunction or those requiring intraoperative ventilation. The postoperative availability of NIV devices may facilitate extubation, support weaning, and help prevent secondary respiratory deterioration [58]. However, weakness of facial or upper airway muscles may complicate or even preclude the initiation of NIV [17].

Patients who use NIV preoperatively should resume it postoperatively. Those who routinely employ cough-assist or airway clearance devices should bring their own equipment and continue their usual regimen [14, 45]. In selected cases, NIV may also be successfully applied prophylactically in the postoperative setting to prevent respiratory failure, which may result from respiratory muscle fatigue induced by GA and surgical stress [59].

Involving the patient's primary caregiver in PACU can greatly assist with device handling and communication. Familiar aids such as alphabet boards or computer-based eye-tracking text systems may further facilitate interaction [14, 60].

Routine postoperative oxygen administration is not recommended, as ALS patients often display instability of respiratory control, and their ventilatory drive during sleep depends primarily on oxygen saturation levels [14, 45].

Bulbar symptoms, such as dysphagia or dysarthria, as well as cognitive impairment, may contribute to malnutrition, necessitating intravenous or enteral feeding during prolonged hospital stays. Since ALS is associated with a hypermetabolic state and increased caloric requirements, postoperative nutritional support is particularly important to prevent further weight loss [10, 38].

Adequate postoperative analgesia is essential to promote effective respiration and prevent hypoventilation due to pain. However, opioid use must be approached cautiously, as these agents may cause respiratory depression. Conversely, insufficient pain control may also impair respiratory effort [30]. Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used when not contraindicated.

Early postoperative physical therapy can be beneficial, especially for the chest and breathing [38].

Disease-related acute problems and effect on anesthesia and recovery

Differential diagnosis: Conditions that may mimic or coexist with ALS include peripheral neuropathy, Lyme disease, vitamin B12 deficiency, thyroid disease, and metal toxicity [1].

Emergency-like situations: Potential acute complications include aspiration, pneumonia, respiratory exhaustion or failure, and hypoxemia.

Ambulatory anesthesia

There are no general recommendations regarding outpatient procedures in ALS patients due to limited data available in the literature. However, ambulatory anesthesia may be feasible in institutions with appropriate resources and expertise. Minor procedures requiring only minimal sedation can be performed safely in an outpatient setting [4].

Nevertheless, most perioperative complications in ALS are not related to the procedure itself but arise as consequences of the underlying disease. Therefore, for more extensive surgeries – or when pre-existing respiratory impairment, the intraoperative need for invasive ventilation, or the absence of adequate professional homecare (e.g., monitoring, nursing service, or home oxygen therapy) is anticipated – hospital admission is recommended [4].

Obstetrical anesthesia

The combination of ALS and pregnancy is extremely rare, as the disease predominantly affects men and typically manifests in the fifth or sixth decade of life. Consequently, data on ALS and pregnancy are limited. Nevertheless, women with ALS are generally fertile. The relationship between hormonal changes during pregnancy and a potential increased

susceptibility to ALS remains under discussion, and it is still unclear whether pregnancy influences the course of ALS – or vice versa [9, 30].

Depending on disease progression, pregnant women with ALS may require hospital admission for monitoring during pregnancy. The timing and mode of delivery depend largely on the individual course and severity of the disease. Because motor neuron diseases do not affect the sensory or motor innervation of the uterus, vaginal delivery is generally possible (and preferred) [9, 30]. However, complications such as progressive respiratory distress or insufficient oxygen supply during labor due to respiratory muscle weakness may necessitate an (emergency) cesarean section [30].

Respiratory function is typically the most affected system during pregnancy, and deterioration should be anticipated regardless of the delivery mode. The physiologic increase in cardiovascular workload and in tidal and minute ventilation that occur during pregnancy may be impaired in ALS due to diaphragmatic and intercostal muscle weakness. During labor, affected parturients may be unable to adequately increase ventilation to meet the oxygen demands. Furthermore, diaphragmatic elevation during the third trimester reduces FRC, which further compromises respiratory reserve [61]. Regular assessment of respiratory and pulmonary function is therefore recommended throughout pregnancy. Notably, lower abdominal procedures such as cesarean section are associated with postoperative lung volume reduction lasting up to two weeks [9, 50, 62].

To mitigate pregnancy-associated risks of difficult airway management and aspiration of gastric content – both of which pose additional challenges in ALS patients – neuraxial anesthesia (epidural, spinal, or CSE) is preferred over GA for delivery. Epidural analgesia during labor may also minimize maternal respiratory efforts [30]. However, neuraxial anesthesia can affect intercostal muscle function and potentially impair spontaneous ventilation [62]. In addition, concerns exist that neuraxial techniques in ALS patients undergoing cesarean section may exacerbate pre-existing disease symptoms [63]. As an alternative, bilateral ultrasound-guided TAP block with incision infiltration before delivery and TIVA by TCI after delivery has been reported as a successful approach for cesarean section [64]. In another report, the combination of TAP block and local infiltration of the incision site was successfully used to avoid neuromuscular blockade, employing ketamine and propofol with a laryngeal mask airway and maintenance with subanesthetic concentrations of sevoflurane [63]. Thus, the optimal anesthetic approach remains under discussion [55].

When significant bulbar dysfunction is assumed, GA may be the only effective means of protecting the airway against aspiration. A reported successful anesthetic approach for cesarean section in such cases included topical anesthesia of the trachea and vocal cords, TIVA (propofol, remifentanyl), avoidance of muscle relaxants, and local infiltration of incision site with ropivacaine [55]. Given that succinylcholine is contraindicated and NDMRs are associated with increased risk for both mother and neonate, this combination of short-acting agents may represent a viable alternative.

Riluzole, the standard therapeutic agent for ALS, can be continued during pregnancy [9, 61]. Since motor neuron disease does not directly affect fetal development, neonatal outcomes are generally favorable [9]. Management of pregnant women with ALS requires a multidisciplinary approach involving obstetricians, anesthesiologists, neurologists, neonatologists, nutritionists, and physiotherapists. This team-based strategy supports optimal respiratory function, adequate nutrition, prevention of deep vein thrombosis, and maintenance of mobility [9].

References

1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. *N Engl J Med*. 2017;377(2):162–72.
2. Chang T, Huh J. Delayed neuromuscular recovery after use of sugammadex in a patient with amyotrophic lateral sclerosis: a case report. *Anaesth Pain & Intensive Care*. 2017;21(4):475–8.
3. Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). *Cold Spring Harb Perspect Med*. 2017;7(8).
4. Hoepfer AM, Barbara DW, Watson JC, Sprung J, Weingarten TN. Amyotrophic lateral sclerosis and anesthesia: a case series and review of the literature. *J Anesth*. 2019;33(2):257–65.
5. Chun HR, Chung J, Kim NS, Kim AJ, Kim S, Kang KS. Incomplete recovery from rocuronium-induced muscle relaxation in patients with amyotrophic lateral sclerosis using sugammadex: A case report. *Medicine (Baltimore)*. 2020;99(3):e18867.
6. Orphanet. Amyotrophic lateral sclerosis: Orphanet; 2011 [Available from: <https://www.orpha.net/en/disease/detail/803>. 27 October 2025]
7. Goutman SA, Hardiman O, Al-Chalabi A, Chio A, Savelieff MG, Kiernan MC, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. *Lancet Neurol*. 2022;21(5):480–93.
8. Panchamia JK, Gurrieri C, Amundson AW. Spinal Anesthesia for Amyotrophic Lateral Sclerosis Patient Undergoing Lower Extremity Orthopedic Surgery: An Overview of the Anesthetic Considerations. *Int Med Case Rep J*. 2020;13:249–54.
9. Pathiraja PDM, Ranaraja SK. A Successful Pregnancy with Amyotrophic Lateral Sclerosis. *Case Rep Obstet Gynecol*. 2020;2020:1247178.
10. Porter SB, McClain RL, Robards CB, Paz-Fumagalli R, Clendenen SR, Logvinov, II, et al. Paravertebral block for radiologically inserted gastrostomy tube placement in amyotrophic lateral sclerosis. *Muscle Nerve*. 2020;62(1):70–5.
11. Riva N, Domi T, Pozzi L, Lunetta C, Schito P, Spinelli EG, et al. Update on recent advances in amyotrophic lateral sclerosis. *J Neurol*. 2024;271(7):4693–723.
12. James E, Ellis C, Brassington R, Sathasivam S, Young CA. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. *Cochrane Database Syst Rev*. 2022;5(5):CD006981.
13. Kak M, Issa NP, Roos RP, Sweitzer BJ, Gottlieb O, Guralnick A, et al. Gastrostomy tube placement is safe in advanced amyotrophic lateral sclerosis. *Neurol Res*. 2017;39(1):16–22.
14. Onders RP, Carlin AM, Elmo M, Sivashankaran S, Katirji B, Schilz R. Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. *Am J Surg*. 2009;197(3):386–90.
15. Saigusa H, Yamaguchi S, Nakamura T, Komachi T, Kadosono O, Ito H, et al. Surgical improvement of speech disorder caused by amyotrophic lateral sclerosis. *Tohoku J Exp Med*. 2012;228(4):371–6.
16. Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. *Lancet*. 2022;400(10360):1363–80.
17. Magelssen M, Holmoy T, Horn MA, Fondenaes OA, Dybwik K, Forde R. Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis. *J Neurol*. 2018;265(11):2730–6.
18. D JP, Wright M, J MP, T BR. Perioperative management of patients with amyotrophic lateral sclerosis: A narrative review. *Anaesth Intensive Care*. 2022;50(5):345–60.
19. Trivedi S, Tibrewala N, Balsara KP. Anaesthetic management of a patient with amyotrophic lateral sclerosis undergoing laparoscopic diaphragmatic pacing. *Indian J Anaesth*. 2015;59(10):683–5.
20. Thomas K, Schrager J, Neel R, Brook L. Percutaneous endoscopic gastrostomy tube placement in amyotrophic lateral sclerosis: a case series with a multidisciplinary, team-based approach. *Ann Gastroenterol*. 2020;33(5):480–4.
21. Brylev L, Fominykh V, Chernenkaia V, Chernenkiy I, Gorbachev K, Ataulina A, et al. Stress load and neurodegeneration after gastrostomy tube placement in amyotrophic lateral sclerosis patients. *Metab Brain Dis*. 2021;36(8):2473–82.
22. Bouabdallaoui A, Taouihar S, Yahya N, Adali N, Nassik H. Bulbar-Onset Amyotrophic Lateral Sclerosis Unmasked by General Anesthesia: A Case Report. *Cureus*. 2025;17(5):e84823.
23. Moser B, Lirk P, Lechner M, Gottardis M. General anaesthesia in a patient with motor neuron disease. *Eur J Anaesthesiol*. 2004;21(11):921–3.

24. Hadaya IA, Gray AT, Braehler MR. Baclofen Pump Replacement in a Patient With End-Stage Amyotrophic Lateral Sclerosis: A Case Report Demonstrating Transversus Abdominis Plane Block as the Sole Anesthetic. *A A Pract.* 2018;10(10):251–3.
25. Pinto S, Swash M, de Carvalho M. Does surgery accelerate progression of amyotrophic lateral sclerosis? *J Neurol Neurosurg Psychiatry.* 2014;85(6):643–6.
26. Lee D, Lee KC, Kim JY, Park YS, Chang YJ. Total intravenous anesthesia without muscle relaxant in a patient with amyotrophic lateral sclerosis. *J Anesth.* 2008;22(4):443–5.
27. Nishihara N, Tachibana S, Ikeshima M, Ino A, Yamakage M. Remimazolam enabled safe anesthetic management during tracheostomy in a patient with amyotrophic lateral sclerosis: a case report. *JA Clin Rep.* 2022;8(1):25.
28. Kim HT, Bae JH, Shin YD, Lee JS, Kim YJ, Lee JY. Total intravenous anesthesia without muscle relaxant for pulmonary wedge resection in a patient with amyotrophic lateral sclerosis: a case report. *Am J Transl Res.* 2022;14(5):3554–8.
29. Kusakai M, Sawada A, Kii N, Tokinaga Y, Hirata N, Yamakage M. Epidural anesthesia combined with sedation with dexmedetomidine for appendectomy in a patient with amyotrophic lateral sclerosis: a case report. *JA Clin Rep.* 2018;4(1):82.
30. Kock-Cordeiro DBM, Brusse E, van den Biggelaar RJM, Eggink AJ, van der Marel CD. Combined spinal-epidural anesthesia with non-invasive ventilation during cesarean delivery of a woman with a recent diagnosis of amyotrophic lateral sclerosis. *Int J Obstet Anesth.* 2018;36:108–10.
31. Thampi SM, David D, Chandy TT, Nandhakumar A. Anesthetic management of a patient with amyotrophic lateral sclerosis for transurethral resection of bladder tumor. *Indian J Anaesth.* 2013;57(2):197–9.
32. Dripps RD, Vandam LD. Exacerbation of pre-existing neurologic disease after spinal anesthesia. *N Engl J Med.* 1956;255(18):843–9.
33. Schmid AB, Coppieters MW. The double crush syndrome revisited—a Delphi study to reveal current expert views on mechanisms underlying dual nerve disorders. *Man Ther.* 2011;16(6):557–62.
34. Hara K, Sakura S, Saito Y, Maeda M, Kosaka Y. Epidural anesthesia and pulmonary function in a patient with amyotrophic lateral sclerosis. *Anesth Analg.* 1996;83(4):878–9.
35. Hobalka AB, Neves BS. Combined spinal-epidural block in a patient with amyotrophic lateral sclerosis: case report. *Rev Bras Anesthesiol.* 2009;59(2):206–9.
36. Sertoz N, Karaman S. Peripheral nerve block in a patient with amyotrophic lateral sclerosis. *J Anesth.* 2012;26(2):314–5.
37. Mishra P, Govil N, Parameswaran P, Gupta B. Transverse abdominis plane block for surgical anesthesia in a patient with flail arm syndrome. *Korean J Anesthesiol.* 2020;73(3):257–8.
38. Thakur UK, Kaman L, Singh C, Kumar M, Bhukal I, Shree R. Whipple's pancreaticoduodenectomy for cancer of the head of the pancreas in a patient with amyotrophic lateral sclerosis: perioperative challenges. *Ann R Coll Surg Engl.* 2021;103(2):e72–e3.
39. Chen Y, Lei XH, Qing AL, Yuan XM. Bilateral dual transversus abdominis plane block for laparoscopic cholecystectomy in a patient with amyotrophic lateral sclerosis. *Asian J Surg.* 2023;46(9):3904–5.
40. Morrell DJ, Chau MH, Winder JS, Stredny ES, Alli VV, Sinz EH, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: outcomes of a dedicated anesthesia and surgery protocol. *Surg Endosc.* 2023;37(6):4338–44.
41. Narayan MS, Sameer M, Viburajah V. Hip Fracture in a Patient with Overlap Syndrome - Conundrums Involved in the Management - A Case Report. *J Orthop Case Rep.* 2023;13(11):106–11.
42. Samworth AG, Miller K, Haswah M, Tureanu L, Weeks J. Neuraxial and Regional Anesthesia in a Patient With Amyotrophic Lateral Sclerosis: A Case Report. *Cureus.* 2023;15(4):e37364.
43. Kaur B, Samagh N, Narang A, Paliwal S. Anesthetic Management of a Neurosurgical Patient With Amyotrophic Lateral Sclerosis: A Case Report. *Cureus.* 2024;16(7):e64492.
44. Li Y, Hu Q, Wang Q, Liu T, Gao M. Real-time ultrasound-guided sacral plexus block combined with mild sedation for hemorrhoidectomy and hemorrhoidal artery ligation in a patient with amyotrophic lateral sclerosis: a case report. *J Med Case Rep.* 2024;18(1):205.
45. Prabhakar A, Owen CP, Kaye AD. Anesthetic management of the patient with amyotrophic lateral sclerosis. *J Anesth.* 2013;27(6):909–18.
46. McKee HR, Escott E, Damm D, Kasarskis E. Macroglossia in amyotrophic lateral sclerosis. *JAMA Neurol.* 2013;70(11):1432–5.
47. Matsuda C, Shimizu T, Nakayama Y, Haraguchi M, Hakuta C, Itagaki Y, et al. Macroglossia in advanced amyotrophic lateral sclerosis. *Muscle Nerve.* 2016;54(3):386–90.

48. Yoo JH, Kim SI, Park SY, Jun MR, Kim YE, Kim HJ. Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis: Case report. *Medicine (Baltimore)*. 2017;96(23):e7098.
49. Park KB, Son B, Hwang DY, Jeon Y. Spinal anesthetic management for discectomy in a patient with amyotrophic lateral sclerosis -A case report. *Korean J Anesthesiol*. 2012;63(6):547–9.
50. Xing Y, Zhang Y, Stabernack CR, Eger EI, 2nd, Gray AT. The use of the potassium channel activator riluzole to test whether potassium channels mediate the capacity of isoflurane to produce immobility. *Anesth Analg*. 2003;97(4):1020–4.
51. Administration USFaD. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) 2019 [Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin>. 27 October 2025
52. You TM, Kim S. Pulseless electrical activity during general anesthesia induction in patients with amyotrophic lateral sclerosis. *J Dent Anesth Pain Med*. 2017;17(3):235–40.
53. Chang YJ, Jung WS, Son WR, Jo YY. Discordance between train-of-four response and clinical symptoms in a patient with amyotrophic lateral sclerosis. *Acta Med Okayama*. 2014;68(2):125–7.
54. Kelsaka E, Karakaya D, Zengin EC. Use of sugammadex in a patient with amyotrophic lateral sclerosis. *Med Princ Pract*. 2013;22(3):304–6.
55. Xiao W, Zhao L, Wang F, Sun H, Wang T, Zhao G. Total intravenous anesthesia without muscle relaxant in a parturient with amyotrophic lateral sclerosis undergoing cesarean section: A case report. *J Clin Anesth*. 2017;36:107–9.
56. Hayashi K, Araki R, Tanaka A. Electroencephalographic monitoring during sevoflurane anaesthesia in an amyotrophic lateral sclerosis patient with locked-in state. *J Clin Neurosci*. 2017;43:126–8.
57. Zeinab EM, Lynn K, Mohammad M, Houssein HA. Meckel's diverticulum in patient with early-onset ALS: A case report. *Int J Surg Case Rep*. 2025;133:111585.
58. Olivieri C, Castioni CA, Livigni S, Bersano E, Cantello R, Della Corte F, et al. Non-invasive ventilation after surgery in amyotrophic lateral sclerosis. *Acta Neurol Scand*. 2014;129(4):e16–9.
59. Koyama Y, Tsuzaki K, Shimizu H, Kuroda J, Shimizu S. Successful bilevel positive airway pressure therapy in a patient with amyotrophic lateral sclerosis after emergency laparotomy: A case report. *Saudi J Anaesth*. 2020;14(4):538–40.
60. Kowalik MM, Smiatacz T, Pajuro R, Skowronski R, Trocha H, Nyka W, et al. Anaesthesia for ophthalmologic surgical procedures in a patient with advanced amyotrophic lateral sclerosis: a case report. *Cases J*. 2008;1(1):338.
61. Amjadi N, Mohammadi S, Paybast S, Dadkhah P, Talayeh M, Asemi Z. A pregnant woman with amyotrophic lateral sclerosis from Iran: a case report. *Ann Med Surg (Lond)*. 2024;86(5):3013–5.
62. Jacka MJ, Sanderson F. Amyotrophic lateral sclerosis presenting during pregnancy. *Anesth Analg*. 1998;86(3):542–3.
63. Wang Y, Zhang Y, Li S, Chen L, Jiang J. Transversus abdominis plane block provides effective and safe anesthesia in the cesarean section for an amyotrophic lateral sclerosis parturient: A case report. *Medicine (Baltimore)*. 2021;100(43):e27621.
64. Li J, Zeng H, Li M, Wang J. Anesthetic management of a parturient with amyotrophic lateral sclerosis undergoing cesarean section. *Chin Med J (Engl)*. 2020;133(11):1371–2.

Date last modified: **January 2026**

This recommendation was prepared by:

Authors

Christine Gaik, Anesthesiologist, Department of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, Campus Marburg and Philipps University of Marburg, Germany
gaikc@med.uni-marburg.de

Thomas Wiesmann, Anesthesiologist, Department of Anesthesiology and Intensive Care Medicine, Diak Klinikum Landkreis Schwäbisch-Hall, Schwäbisch-Hall, Germany
thomas.wiesmann@diak-klinikum.de

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewer 1

Toby Weingarten, Anaesthesiologist, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA
weingarten.toby@mayo.edu

Reviewer 2

David Czell, Neurologist, Rapperswil, Switzerland
david.czell@hin.ch

Disclosure The reviewers have no financial or other competing interest to disclose.

Update and revision (2026)

Christine Gaik, Anesthesiologist, Department of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, Campus Marburg and Philipps University of Marburg, Germany
gaikc@med.uni-marburg.de

Thomas Wiesmann, Anesthesiologist, Department of Anesthesiology and Intensive Care Medicine, Diak Klinikum Landkreis Schwäbisch-Hall, Schwäbisch-Hall, Germany
thomas.wiesmann@diak-klinikum.de

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

Reviewer

Martin Jöhr, Former head of the Division of Pediatric Anaesthesia, Luzerne Hospital (LUKS), Adligenswil, Switzerland
joehrmartin@bluewin.ch

Editorial Review

Philipp Gude, Specialist in anaesthesia and intensive care medicine,
Ruhr University Bochum, Bochum, Germany
St. Elisabeth-Hospital, Bochum, Germany
philipp.gude@kklbo.de

Disclosure The reviewers have no financial or other competing interest to disclose.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e. V.
Präsident: Prof. Dr. G. Marx,
Aachen



BDA

Berufsverband Deutscher
Anästhesistinnen und
Anästhesisten e. V.
Präsidentin: Prof. Dr.
G. Beck, Mannheim

Schriftleitung

Präsident/in der Herausgeberverbände

Gesamtschriftleiter/Editor-in-Chief:

Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt

Stellvertretender Gesamtschriftleiter/

Deputy Editor:

Prof. Dr. T. Volk, Homburg/Saar

CME-Schriftleiter/CME-Editor:

Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Priv.-Doz. Dr. E. Adam, Frankfurt

Prof. Dr. M. Adamzik, Bochum

Dr. J. Aulenkamp, Essen

Prof. Dr. G. Beck, Mannheim

Prof. Dr. T. Brenner, Essen

Prof. Dr. A. Brinkmann, Heidenheim

Prof. Dr. M. Coburn, Bonn

Prof. Dr. S.M. Coldewey, Zürich

Prof. Dr. V. von Dossow, Bad Oeynhausen

Prof. Dr. B. Ellger, Dortmund

Prof. Dr. K. Engelhard, Mainz

Prof. Dr. M. Fischer, Göppingen

Prof. Dr. D. Fries, Innsbruck

Prof. Dr. J.-T. Gräsner, Kiel

Prof. Dr. K. Hahnenkamp, Greifswald

Prof. Dr. A.R. Heller, Augsburg

Prof. Dr. B. Jungwirth, Ulm

Prof. Dr. T. Loop, Freiburg

Prof. Dr. K. Meissner, Göttingen

Prof. Dr. W. Meißner, Jena

Prof. Dr. P. Meybohm, Würzburg

Prof. Dr. T. Müller-Wolff, Ludwigsburg

Prof. Dr. H. Mutlak, Offenbach

Prof. Dr. C. Nau, Lübeck

Prof. Dr. V. Neef, Frankfurt

Prof. Dr. B. O'Brien, Berlin

Dr. B. Oehler, Heidelberg

Prof. Dr. S.G. Sakka, Koblenz

Prof. Dr. M. Sander, Gießen

Prof. Dr. B. Saugel, Hamburg

Prof. Dr. S. Schäfer, Oldenburg

Priv.-Doz. Dr. H. Schöchl, Salzburg

Prof. Dr. A. Steinbicker, Köln

Dr. M.T. Völker, Leipzig

Prof. Dr. N.-M. Wagner, Würzburg

Prof. Dr. F. Wappler, Köln

Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Korrespondenzadresse:

Neuwieder Straße 9 | 90411 Nürnberg |

Deutschland | Tel.: 0911 9337812

E-Mail: redaktion@ai-online.info

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |

97500 Ebelsbach | Deutschland

www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |

Tel.: 09522 9435-0 | Fax: 09522 9435-67

E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Tel.: 09522 9435-70

E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler

Neuwieder Straße 9 | 90411 Nürnberg

Tel.: 0171 9432534

E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Robert Kux | Tel.: 09522 9435-71

E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Roland Mehl

3D Arts GmbH

Dunantstraße 2 | 92224 Amberg

E-Mail: rmehl@3darts.de

www.3darts.de

Erscheinungsweise 2026

Der 67. Jahrgang erscheint 6x pro Jahr

alle zwei Monate, beginnend ab Februar.

**Die A&I ist die Verbandszeitschrift von
DGAI und BDA.**

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem Im-
pressum auf www.ai-online.info

Indexed in **CINAHL**; **Current Contents®/**
Clinical Medicine; **EBSCO**; **EMBASE/**
Excerpta Medica; **Medical Documen-**
tation Service; **Research Alert**;
Sci Search; **Scopus**; **SUBIS Current**
Awareness in Biomedicine; **VINITI**;
Russian Academy of Science.

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urheber-
rechtlich geschützt. Jegliche Art von Ver-
vielfältigungen – sei es auf mechanischem,
digitalem oder sonst möglichem Wege –
bleibt vorbehalten. Die Aktiv Druck & Ver-
lags GmbH ist allein autorisiert, Rechte zu
vergeben und Sonderdrucke für gewerb-
liche Zwecke, gleich in welcher Sprache,
herzustellen. Anfragen hierzu sind nur an
den Verlag zu richten. Jede im Bereich ei-
nes gewerblichen Unternehmens zulässig
hergestellte oder benutzte Kopie dient ge-
werblichen Zwecken gem. § 54 (2) UrhG.
Die Wiedergabe von Gebrauchsnamen,
Handelsnamen, Warenbezeichnungen
usw. in dieser Zeitschrift berechtigt auch
ohne besondere Kennzeichnung nicht zu
der Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-Ge-
setzgebung als frei zu betrachten wären
und daher von jedermann benutzt werden
dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanweisun-
gen und Applikationsformen kann vom
Verlag und den Herausgebern keine Ge-
währ übernommen werden. Derartige An-
gaben müssen vom jeweiligen Anwender
im Einzelfall anhand anderer Literaturstel-
len auf ihre Richtigkeit überprüft werden.
Gleiches gilt für berufs- und verbands-
politische Stellungnahmen und Empfeh-
lungen.

Der Verlag veröffentlicht die Beiträge in der
von den Autorinnen und Autoren gewählten
Genderform.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-933780
Email: info@orphananesthesia.eu